<DOC>
	<DOCNO>NCT00778102</DOCNO>
	<brief_summary>This 2 arm study compare resection rate liver metastases safety surgery patient metastatic colorectal cancer primarily unresectable liver metastasis receive treatment Avastin combination 5-FU , leucovorin oxaliplatin irinotecan ( FOLFOXIRI ) without irinotecan ( mFOLFOX-6 ) first line treatment . Patients randomize receive Avastin ( 5mg/kg iv every 2 week ) combination two standard neoadjuvant chemotherapy regimen . The anticipated time study treatment surgery , disease progression , unacceptable toxicity patient refusal , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With mFOLFOX-6 FOLFOXIRI Patients With Metastatic Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; unresectable liver metastasis secondary cancer colon rectum ; schedule standard first line chemotherapy ; ECOG performance score 0 1 ; condition feasible major abdominal surgery first line treatment . diagnosis metastatic disease &gt; 3 month prior study entry ; evidence extrahepatic disease , diffuse peritoneal carcinosis involvement celiac lymph node ; prior systemic local treatment metastatic disease ; prior ( neo ) adjuvant chemotherapy/radiotherapy complete within 6 month prior study entry ; history evidence CNS disease unrelated cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>